Dabrafenib is named as an intervention in 11 current clinical trials in our China, USA, UK and India registers. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Novartis Pharmaceuticals (3). The most-studied condition is Solid Tumor.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Solid Tumor | 2 |
| Diffuse Astrocytoma | 1 |
| Anaplastic Astrocytoma | 1 |
| Astrocytoma | 1 |
| Oligodendroglioma, Childhood | 1 |
| Advanced Solid Tumor | 1 |
| Pancreatic Adenocarcinoma | 1 |
| Malignant Melanoma (Cutaneous) | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
| Differentiated Thyroid Cancer (DTC) | 1 |
| Melanoma | 1 |
| Non Small Cell Lung Cancer | 1 |
| Rare Cancers | 1 |
| Lung Cancer Stage III | 1 |
| Mutation | 1 |
| BRAF V600E | 1 |
| Colorectal Cancer | 1 |
| Sintilimab | 1 |
| MSS (Microsatellite Stable) | 1 |
| Precision Medicine | 1 |
| Thyroid Neoplasms | 1 |
| Langerhans Cell Histiocytosis (LCH) | 1 |
| NSCLC | 1 |
| BRAF V600 Mutation | 1 |
| MET Exon 14 Mutation | 1 |
| Locally Advanced Thyroid Gland Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| Sun Yat-sen University | 2 |
| Immuneering Corporation | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Tianjin Medical University Second Hospital | 1 |
| Fujian Medical University | 1 |
| West China Second University Hospital | 1 |
| West China Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 6 |
| Clinical trials in USA | 4 | 1 |
| Clinical trials in UK | 1 | 0 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
11 current trials in our China, USA, UK and India registers name Dabrafenib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 11 trials are recruiting: 6 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Novartis Pharmaceuticals (3), Sun Yat-sen University (2), Immuneering Corporation (1) and Tianjin Medical University Cancer Institute and Hospital (1), among 8 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dabrafenib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dabrafenib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dabrafenib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.